DLK Investment Management LLC Invests $402,000 in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• DLK Investment Management LLC purchased 765 shares of Regeneron Pharmaceuticals, valued at approximately $402,000, marking a new position in the biopharmaceutical company during the second quarter.
• Regeneron reported earnings of $12.89 per share for the most recent quarter, exceeding the consensus estimate by $4.46, with revenues of $3.68 billion.
• The company announced a quarterly dividend of $0.88 per share, which reflects a yield of 0.6% and a low payout ratio of 8.87%.

DLK Investment Management LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 765 shares of the biopharmaceutical company's stock, valued at approximately $402,000.

A number of other hedge funds also recently bought and sold shares of REGN. GAMMA Investing LLC raised its holdings in Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $343,764,000. Pacer Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after acquiring an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Regeneron Pharmaceuticals by 171.0% in the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after acquiring an additional 303,785 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Regeneron Pharmaceuticals by 30.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after acquiring an additional 226,952 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on REGN shares. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Raymond James Financial upgraded Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Sanford C. Bernstein increased their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Finally, Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Stock Down 1.1%

NASDAQ REGN traded down $6.72 during trading on Friday, reaching $591.99. 2,177,965 shares of the company's stock were exchanged, compared to its average volume of 1,100,130. The stock has a market cap of $62.75 billion, a P/E ratio of 14.92, a price-to-earnings-growth ratio of 1.96 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a 50 day moving average price of $567.29 and a two-hundred day moving average price of $576.47. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,154.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's revenue was up 3.6% on a year-over-year basis. During the same period last year, the firm posted $11.56 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.